Skip to main navigation

Contact Us

Investor Relations

Our Company
Product Candidates
- Pipeline
- MultiTAA Therapies
Our Science
Clinical Trials
- Active Clinical Trials
- Expanded Access Policy
Investors/Media
Careers

Investors/Media

Quarterly Results

Quarterly Results

Show all

2022

First Quarter

Marker Therapeutics Reports Q1 2022 Operating and Financial Results
Form 10-Q

2021

Fourth Quarter

Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results
Form 10-K

Third Quarter

Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results
Form 10-Q

Second Quarter

Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results
Form 10-Q

First Quarter

Marker Therapeutics First Quarter 2021 Financial and Operating Results
Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results
Form 10-Q

2020

Fourth Quarter

Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results
Form 10-K

Third Quarter

Marker Therapeutics Third Quarter 2020 Financial and Operating Results
Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results
Form 10-Q

Second Quarter

Marker Therapeutics Reports Second Quarter 2020 Operating and Financial Results
Form 10-Q

First Quarter

Marker Therapeutics Reports First Quarter 2020 Operating and Financial Results
Form 10-Q

2019

Fourth Quarter

Marker Therapeutics Reports Full Year 2019 Operating and Financial Results
Form 10-K

Third Quarter

Marker Therapeutics Reports Third Quarter 2019 Operating and Financial Results
Form 10-Q

Second Quarter

Marker Therapeutics Reports Second Quarter 2019 Operating and Financial Results
Form 10-Q

First Quarter

Marker Therapeutics Reports First Quarter 2019 Operating and Financial Results
Form 10-Q

Investors/Media

Investors/Media Home
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials & Filings
Corporate Governance
Investor Resources

IR and Media Contacts

Marker Therapeutics

Neda Safarzadeh
Vice President/Head of Investor Relations, PR & Marketing
(713) 400-6451
investor.relations@markertherapeutics.com

Solebury Trout

Investors

Xuan Yang
xyang@soleburytrout.com

Media

Amy Bonanno
abonanno@soleburytrout.com

investor.relations@markertherapeutics.com
(713) 400-6400

©2022 Marker Therapeutics, Inc. All Rights Reserved.

Footer Links

Sitemap
Terms of Use
Privacy Policy